

Development of a bispecific antibody targeting **** biparatopically for treating cancer-associated pulmonary embolism

MabTics Co., Ltd.



CARDIOVASCULAR	Candidate
Product Type	Antibody
Indication	Cancer-associated Pulmonary Embolism (PE)
Target	****, hereinafter referred to as pathological thrombosis target (PTT)
MoA(Mechanism of Action)	• Inhibition of PTT enzymatic activity - Biparatopic occupancy of adjacent epitopes within a functional domain of PTT and suppression of PTT-mediated catalytic activity • Inhibition of the interaction between PTT and substrates - Suppression of PTT-mediated substrate activation and binding amplification • Blockade of platelet aggregation pathways - Inhibition of platelet-platelet and platelet-immune cell interactions • Blockade of blood coagulation - Suppression of FXI/FIX-mediated intrinsic and TF-mediated extrinsic coagulation pathways • Preservation of physiological hemostasis - Selective targeting of extracellular PTT and preservation of physiological coagulation
Competitiveness	• First-in-class bispecific antibody approach targeting PTT • Selective control of pathological inflammatory thrombosis rather than physiological hemostasis • Potential differentiation from conventional antiplatelet agents and FXIa/Xa inhibitors • Novel therapeutic strategy for high-risk cancer patients with recurrent thrombosis and bleeding concerns
Development Stage	Candidate
Route of Administration	Intravenous (IV) administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.